Lysodren

mitotane · Esteve Pharmaceuticals, S.A.
AUTHORISED IN THE EU

What Lysodren is used for

Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Lysodren
Active substance
mitotane
Disease area
Adrenal Cortex Neoplasms
Medicine group
Antineoplastic agents
ATC code
L01XX23
Marketing authorisation holder
Esteve Pharmaceuticals, S.A.
Authorised in the EU since
2004

Official information

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Lysodren used for?

Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established.

What is the active substance in Lysodren?

Lysodren contains mitotane.

Who makes Lysodren?

The EU marketing authorisation holder is Esteve Pharmaceuticals, S.A..

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.